Tricuspid regurgitation (TR) is difficult to manage and is a mortality predictor. At present, surgery is recommended, even though its mortality rate is not low.
Endovascular intervention of this entity is currently being developed and according to the European guidelines, it has evidence level IIb C in symptomatic inoperable patients.
The TriCLASP included 74 patients with severe +) symptomatic high-risk TR (≥3 eligible for PASCAL or PASCAL Ace.
Mean age was 80, 58% were women, 30% diabetic, the were mostly in functional class III-IV, 96% had atrial fibrillation, 23% definite pacemaker or ICD, 36% prior SAVR or TAVR and more than half presented deteriorated renal function.
Mortality STS Score was 9%.
The cause of TR was functional in 84.2%, degenerative in 5.3% and mix 10.5%.
Read also: EuroPCR 2022 | The IMPROVED-CTO Trial.
Implantation success rate was 97%, 1.8 device per patients were implanted, hospital stay was 5 days.
At 30 days, cardiovascular mortality was seen in 1 patient, non-cardiovascular mortality in 2, stroke in one, as well as dialysis and severe bleeding, and 3 patients were rehospitalized for cardiac failure. There were no MIs, reinterventions, bleeding, or major vascular complications.
There was significant reduction of TR both in hospital and at 30 days, improved functional class, quality of life and 6-minute walk test outcomes.
Dr. Carlos Fava.
Member of the Editorial Board of SOLACI.org.
Subscribe to our weekly newsletter
Get the latest scientific articles on interventional cardiology
